PharmAust Limited (ASX: PAA), a clinical-stage biotechnology company evaluating the use of Monepantel (MPL) in Cancer and Motor Neurone Disease (MND), has been issued a Notice to Grant for a key patent relating to the use of MPL Combinations in Cancer, from the European Patent Office.
The Patent covers pharmaceutical combinations between MPL and other drugs that treat cancer. Combination-drug therapy is widespread in cancer treatment, where the therapeutic regimen aims to minimise the possibility of drug resistance.
This key patent coverage relates to pharmaceutical combinations comprising mTOR pathway- interfering drugs and anticancer compounds for particular use in cancer treatment.
mTOR pathway-interfering drugs refer to different drugs which stop the signalling pathway in our cells that help their growth and survival. PharmAust is trialling MPL and other drug combinations to interfere with this pathway as a potential way to treat cancer and neurodegenerative diseases.
The key patent will be published on 8 March 2023 under number EP3062790. PharmAust will receive the Certificate of Grant and the published patent specification.
This patent extends PharmAust’s existing patent coverage, including granted patents in Australia, the US, China, Japan, Korea, Canada and New Zealand.
